A worrying aspect of the COVID-19 outbreak, so far as drugmakers and patients are concerned, is that the virus has taken an unerring liking to regions that also happen to be the major production centers for many of the world’s medicines.
The point was made partly in jest by Adrian van den Hoven (pictured above, center), one of the most important figures in ensuring medicine supply to Europe, but he made it to underline the extent of the challenge that the industry could be facing.
Mr van den Hoven is director general of Medicines for Europe, the trade group for generics and biosimilars manufacturers that jointly organized an event in Brussels on Tuesday in the context of new European Commission healthcare priorities. The other organizer was the Hungarian Permanent Representation to the European Union (EU), under the auspice of the Croatian Presidency to the European Council.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze